Publications

Title

Author

Year

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.

Moorthy, VS; Imoukhuede, EB; MILLIGAN, P; BOJANG, K; Keating, S; Kaye, P; Pinder, M; Gilbert, SC; Walraven, G; GREENWOOD, BM; Hill, AS V;

2004

PLoS medicine, (2004).1 2 10.1371/journal.pmed.0010033.

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

Melegaro, A; EDMUNDS, WJ;

2004

Vaccine, (2004).22 31-32 10.1016/j.vaccine.2004.05.003.

Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria.

Cavanagh, DR; Dodoo, D; Hviid, L; Kurtzhals, JA L; Theander, TG; Akanmori, BD; POLLEY, S; CONWAY, DJ; Koram, K; McBride, JS;

2004

Infection and immunity, (2004).72 11 10.1128/IAI.72.11.6492-6502.2004.

The seroepidemiology of Bordetella pertussis infection in Western Europe.

Pebody, RG; Gay, NJ; Giammanco, A; Baron, S; Schellekens, J; Tischer, A; Olander, RM; Andrews, NJ; EDMUNDS, WJ; Lecoeur, H; Lévy-Bruhl, D; Maple, PA C; De Melker, H; Nardone, A; Rota, MC; Salmaso, S; Conyn-van Spaendonck, MA E; Swidsinski, S; MILLER, E;

2004

Epidemiology and infection, (2004).133 1 10.1017/s0950268804003012.

MMR vaccination and pervasive developmental disorders: a case-control study.

SMEETH, L; Cook, C; Fombonne, E; Heavey, L; RODRIGUES, LC; SMITH, PG; Hall, AJ;

2004

Lancet, (2004).364 9438 10.1016/S0140-6736(04)17020-7.

Use of vaccine trials to estimate burden of disease.

MULHOLLAND, EK;

2004

Journal of health, population, and nutrition, (2004).22 3

Variation in the costs of delivering routine immunization services in Peru.

Walker, D; Mosqueira, NR; Penny, ME; Lanata, CF; CLARK, AD; SANDERSON, CF B; Fox-Rushby, JA;